Background/Aims: Rapamycin (Rp), the main mammalian target of rapamycin complex inhibitor, is a promising therapeutic agent for breast cancer. However, metabolic disorders and drug resistance reduce its efficacy. Epidemiological, clinical, and experimental studies have demonstrated that omega-3 polyunsaturated fatty acids (ω-3 PUFAs) significantly reduce the incidence and mortality of breast cancer and improve metabolic disorders. Methods: Three breast cancer cell lines and immunocompetent and immunodeficient mice were used to evaluate the therapeutic effects of Rp plus ω-3 PUFA treatment. The production of reactive oxygen species (ROS) and glucose uptake were examined by flow cytometry. Metabolic shift was examined by metabonomics, seahorse experiments, and western blot analysis. Results: We found that ω-3 PUFAs and Rp synergistically induced cell cycle arrest and apoptosis in vitro and in vivo, accompanied by autophagy blockage. In addition, Rpinduced hypertriglyceridemia and hypercholesterolemia were completely abolished by ω-3 PUFA supplementation. Moreover, the combined treatment of ω-3 PUFA and Rp significantly inhibited glycolysis and glutamine metabolism. The anti-tumor effects of this combination treatment were dependent on ROS production, which was increased by β-oxidation and oxidative phosphorylation. Conclusion: Our study revealed that ω-3 PUFA enhanced the antitumor activity of Rp while minimizing its side effects in vitro and in vivo. These results provide novel insights into the mechanisms underlying the potential beneficial effects of Rp combined with ω-3 PUFAs on the prevention of breast cancer.
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Effect DCFH-DA is oxidized to dichlorodihydrofluorescein (DCF) in the presence of ROS, so DCF fluorescence was analyzed by FACS Calibur flow cytometry.
In vitro oxygen consumption and glycolysis
The in vitro oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in MDA-MB-231 cells were determined using the Seahorse XF24 Extracellular Flux Analyzer as previously described [22] . Briefly, 20, 000 cells were seeded in the XFE24 microplate with complete media. Then, 6 h after seeding, cells were treated with the indicated concentrations of ω-3 PUFAs (40 μM) and/or Rp (10 μM) and incubated for 6 h. After incubation, the complete medium was removed and replaced with 150 μL bicarbonate-free medium in a CO 2 -free incubator for 1 h before analysis. The basal mitochondrial respiration (OCR) was measured, and the ECAR was measured as a surrogate for lactate production and glycolysis. Data were normalized by cell number per well and quantified using Operetta (image-based quantification).
Metabolic assays
Malondialdehyde (MDA), lactate production, and ATP levels were measured using assay kits from BioVision (San Francisco, CA). Metabolites were determined by gas chromatography-mass spectrometry (GC-MS). The cells are quenched in 60% methanol supplemented with 0.85% (wt/vol) ammonium bicarbonate at -40°C. Then, metabolites were extracted from the quenched cells by two 100% methanol extractions followed by a single water extraction. The metabolite samples generated using this protocol were amenable to analysis by GC-MS as previously described [23] .
Xenograft breast cancer model and treatment
The animal protocol was approved by the Jiangnan University Animal Care and Use Committee (Jiangsu Sheng, China). Female nude mice (purchased from Slaccas, Shanghai, China) aged 4 to 5 weeks received injections of 4 × 10 5 breast cancer cells (MDA-MB-231). Two weeks later, mice with similar tumor masses were randomized into four treatment groups: control (vehicle), EPA (3 g in 100 g diet), Rp (5 mg in 100 g diet), and EPA and Rp combination treatment. The mice were treated for 2 weeks. Tumor sizes were measured twice a week. The tumor volumes were calculated using the following formula: volume = ½ × length × width 2 . The mice were sacrificed after the treatment period. Blood was collected from the retroorbital sinus of each non-anesthetized mouse to measure biochemical indexes including serum levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), lowdensity lipoprotein cholesterol (LDL-C), and MDA. Analyses were conducted using the BS-480 Clinical Chemistry Analyzer (Mindray Medical International Ltd., Shenzhen, China) according to the manufacturer's instructions. Paraformaldehyde-fixed tumor tissues were embedded in paraffin and sectioned (4 mm). The sections were treated with 0.3% hydrogen peroxide/methanol and incubated with monoclonal antibodies, followed by incubation with Histostain-Plus IHC Kit (Thermo Fisher Scientific, Waltham, MA, USA) reagents according to the manufacturer's instructions.
MMTV-PyVT mammary tumor model
The MMTV-PyVT (polyoma virus middle T oncogene) mammary tumorigenesis mouse model was obtained from the Model Animal Research Center of Nanjing University (Jiangsu Sheng, China). Female MMTV-PyVT mice were used in this study. Mice aged 6 weeks with similar body weight were randomized into five treatment groups: control (vehicle), EPA (3 g in 100 g diet), Rp (5 mg in 100 g diet), EPA+Rp, and RP+EPA+N-acetyl-L-cysteine (NAC). The mice were treated for 4 weeks. Body weight was measured weekly. All tumors were excised and weighed. The mice were sacrificed after the treatment period. Blood was collected from the retroorbital sinus of each non-anesthetized mouse to measure biochemical indexes including serum levels of TG, TC, HDL-C, LDL-C, and MDA.
Statistical analysis
All animal experiments were approved by the Ethics Committee of Jiangnan University. Data were reported as the mean ± standard error of the mean (SEM). Statistical significance was determined by oneway analysis of variance followed by the Dunnett's test for multiple comparisons. Statistical analyses were performed using SPSS software (version 20.0; SPSS Inc., Chicago, IL). P values less than 0.05 were considered statistically significant. For western blot analyses, one representative set of data is shown. 
, and TNBC [24] . Three human breast carcinoma cell lines (MCF-7, SKBR-3, and MDA-MB-231) were used to determine the combined effects of Rp and ω-3 PUFAs for treating various subtypes of breast cancer. Cells were treated with Rp, ω-3 PUFAs, or Rp+ω-3 PUFAs for up to 3 days. As shown in Fig. 1A , EPA and DHA had no significant inhibitory effects at concentrations below 40 μM. Rp exhibited no significant cytotoxicity in the three cell lines at concentrations below 10 μM. Based on these results, 40 μM ω-3 PUFAs and 10 μM Rp were used in the combination treatment. The combination treatment significantly reduced the cell count in all of the breast cancer cell lines. Maximal inhibition of 78% compared with untreated cells was achieved by day 3 in the combined Rp and DHA or EPA treatment groups (Fig. 1B) . Overall, these results demonstrated that ω-3 PUFAs and Rp synergistically inhibited the cell growth of not only ER + and HER2 + but also TNBC cells. To investigate whether cell cycle arrest causes the inhibition of cell growth, we used flow cytometry to analyze cell cycle progression following treatment with single ω-3 PUFAs, Rp, and a combination of ω-3 PUFA+Rp. Compared with untreated cells, in the treated cells, each drug individually caused no significant change in cell cycle distribution. However, the combination of ω-3 PUFA+Rp induced the significant accumulation of cells in the G0/G1 phase coupled with a marked reduction of cells in the S and G2/M phases of the cell cycle of SKBR-3 and TNBC cells. In MCF-7 cells, the significant accumulation of cells in the G2/M phase and marked reduction of cells in the S and G0/G1 phases of the cell cycle were observed (Fig. 1C) . To further investigate the mechanisms underlying combination treatment-induced cell cycle arrest, we examined the expression of p21, p27, and cyclin D1, which plays important roles in the regulation of cell cycle arrest [25] . Western blotting results showed that cyclin D1 expression in all three subtypes of breast cancer cells was not dramatically altered by ω-3 PUFAs, Rp, and ω-3 PUFA+Rp (Fig. 1D) . However, compared to single reagents, the combination of ω-3 PUFAs and Rp markedly decreased the expression of p21 and p27 in all three breast cancer cell lines, showing the synergistic suppressive effects on p21 and p27 expression (Fig. 1D ).
ω-3 PUFA and Rp synergistically promote cell apoptosis
In addition to cell cycle arrest, cell apoptosis can cause the inhibition of cell growth. Hence, we investigated whether apoptosis was induced by ω-3 PUFAs, Rp, and ω-3 PUFA+Rp. By flow cytometry analysis of Annexin V/PI-stained cells, we found that the population of apoptotic cells in all three cell lines was remarkably elevated following incubation with ω-3 PUFA+Rp combined treatment compared with single ω-3 PUFA or Rp treatment, indicating that ω-3 PUFAs and Rp had synergistic effects on the induction of cell apoptosis in all three cell lines ( Fig. 2A, B) . As is well known, cleaved-poly(ADP-ribose) polymerase (PARP) and the reduction of Bcl-2 act as key indicators of apoptosis [26] . To investigate whether the cleavage product of PARP and the expression of Bcl-2 could be altered by single or combination treatment, we examined the protein level of both cleaved PARP and Bcl-2 in cells following ω-3 PUFA and Rp treatment and ω-3 PUFA+Rp combination treatment. Western blot analysis revealed that the combined treatment of ω-3 PUFAs and Rp significantly increased the level of cleaved PARP and markedly decreased the Bcl-2 protein level compared with single drug treatment, which showed the synergistic effects of ω-3 PUFA+Rp on the expression of both cleaved PARP and Bcl-2 ( Fig. 2C) . Furthermore, Z-VAD-FMK, which is generally used as an apoptosis inhibitor [27] , significantly prevented the combination of ω-3 PUFA+Rp-induced cell death in all breast cancer cell lines (Fig. 2D ). These results suggest that the combination of ω-3 PUFA+Rp synergistically induce breast cancer cell apoptosis.
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Combination treatment of Rp and ω-3 PUFAs blocks autophagic flux
Numerous reports have been published on the relationship between autophagy and cancer progression and initiation. In response to environmental stresses (e.g., nutrient starvation, hypoxia, infections), autophagy is upregulated to provide the energy supply needed for cell survival and repair [28] , and recent studies have shown that the induction of autophagy facilitates cancer cell resistance to Rp-induced apoptosis [29] . Previous studies [19, 30] . Thus, we determined whether autophagy plays a key role in the synergistic effects caused by ω-3 PUFA+Rp combination treatment. Neither Rp nor ω-3 PUFAs had significant effects on LC3II expression (an autophagosome biomarker) in the breast cancer cell lines (Fig. 3A) . However, the combination of Rp and ω-3 PUFAs caused a significant increase in LC3II/β-actin in all of the breast cancer cell lines tested coupled with a marked decrease in formation of the autophagy elongation complex (ATG5-12) complex, which is a key step in autophagosome biogenesis [31] , suggesting that combination treatment may inhibit autophagy initiation and the fusion of autophagosomes with lysosomes. Autophagy is a highly dynamic process in mammalian cells. Therefore, monitoring autophagic flux is necessary for determining the rate of autophagy [32, 33] . Autophagic flux was measured by comparing LC3II/β-actin levels in the cases of combination treatment with or without CQ (by increasing lysosomal pH) and long-lived protein p62 degradation. These two general methods for 
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Effect by multiple signaling pathways including the mTOR and Beclin-1 pathways [36, 37] . Because mTOR is a negative regulator of autophagy, its activation leads to suppression of autophagic vesicle formation. mTOR phosphorylation at S2448 and p70S6 kinase phosphorylation at T389, which are inhibited by Rp, are widely used as markers of mTOR activity [38] . Western blot analyses of the mTOR kinase substrate, p70S6 kinase, and p-mTOR were used to determine whether Rp+ω-3 PUFAs modulated autophagic flux by affecting mTOR activity. Rp significantly inhibited the levels of p-mTOR and p-S6K, whereas no significant differences were found between the single Rp-treated and combination-treated groups (Fig.  3C) . Recent studies have established that insulin induces p70S6 kinase phosphorylation by activating mTOR [39, 40] . Therefore, we used insulin as an mTOR activator to determine whether mTOR activation can prevent the accumulation of LC3II by treatment with Rp+ω-3PUFAs. The results revealed that the addition of insulin had no significant effect on signal transduction or cell death (Fig. 3D, E) . The second major protein complex that controls autophagic activity is Beclin-1. No significant differences in the concentrations of Beclin-1 and UVRAG were observed between the cancer cell treatment groups (Fig. 3C) . Furthermore, we determined that 3-MA, which is widely used as a class III phosphatidylinositol 3-kinase (PI3K) inhibitor, inhibited the induction of autophagy upon treatment with Rp+ω-3 PUFAs. Consistent with the results shown in Fig. 3C , there were no significant differences between cells treated with or without 3-MA (Fig. 3D, E ). These results demonstrate that Rp+ω-3PUFAs modulate autophagic flux independently of mTOR and Beclin-1 complexes.
ω-3 PUFA enhances Rp-induced ROS production ω-3 PUFAs are highly active molecules, and recent studies have suggested that ROS and lipid peroxidation play crucial roles in their anticancer activity [41, 42] . Furthermore, studies have shown that ROS production in cancer cells is one of the mechanisms underlying the synergetic cytotoxicity observed in cases of combination anti-tumor treatments [43, 44] . Therefore, we determined whether ROS generation plays a role in the combined cytotoxic effects of Rp and ω-3 PUFAs. Both Rp and ω-3 PUFAs alone led to slightly higher ROS production than the control as assessed by the levels of DCF, whereas the co-treatment of cells with Rp and ω-3 PUFAs resulted in a significant increase in ROS levels compared to Rp or ω-3 PUFA treatments alone (Fig. 4A) . As expected, the enhanced DCF signal (ROS level) and cell death were significantly blocked when cells were pre-treated with the ROS scavenger NAC (Fig. 4B, C) . These results indicate that the synergistic effects of combination treatment with Rp and ω-3 PUFA on cell death were modulated through ROS production. To determine whether supplementation with fatty acids other than ω-3 PUFAs exhibited the same effects on ROS production, we evaluated the effects of palmitic acid (PA) and oleic acid (OA) as representatives of saturated and monounsaturated fatty acids, respectively. The results showed that neither OA nor PA treatment alone or combined with Rp influenced ROS production in all breast cancer cell types (Fig. 4D) , suggesting that ω-3 PUFAs enhanced Rpinduced ROS production because of their unique fatty acid structure.
Combination treatment with Rp and ω-3 PUFA inhibits glycolysis and glutamine metabolism
Metabolic reprogramming is a hallmark of cancer and has been an area of accelerated research during the last decade [45] . A classical metabolic change in cancer cells is the increased consumption of glucose and glutamine [46, 47] . Numerous studies have demonstrated that the mTOR complex as an energy sensor plays a key role in modulating cancer metabolism. In addition, a recent study reported that ω-3 PUFAs as both a source of fuel but also as a bioactive component participate in cancer metabolism [48, 49] . We determined whether the combination treatment of ω-3 PUFA+Rp treatment induced a shift in cancer metabolism. The significantly decreased expression of key enzymes in glycolysis (hexokinase 2, pyruvate kinase isozyme M2, phosphofructokinase, platelet, and PD, the pentose phosphate pathway, and glutaminase were detected using immunoblotting after in vitro combination treatment (Fig. 5B, C) ; however, the rate of glucose uptake did not change in each group (Fig. 5A, B) 
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Combination treatment increases β-oxidation and oxidative phosphorylation
The combination treatment induced a significant change in fatty acid metabolism and oxidative phosphorylation. Fatty acid metabolism significantly decreased, whereas catabolism increased. The key enzymes involved in β-oxidation and oxidative phosphorylation clearly increased due to the addition of Rp and ω-3 PUFAs (Fig. 6A, B) , suggesting that the combination treatment of Rp and ω-3 PUFAs induces significant metabolic shifts. To further verify the metabolic change, basal OCR and key intermediate metabolites were measured. We found that the basal OCR and metabolites involved in β-oxidation and oxidative phosphorylation (malate, fumarate, and citrate) significantly increased with ω-3 PUFA treatment and the combination treatment (Fig. 6C, D) . Numerous studies have demonstrated that fatty acid oxidation is required for the increased ROS levels [50] . Furthermore, it has been suggested 
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Effect that ω-3 PUFAs have a considerably high affinity to PPARα and that ω-3 PUFA binding induces a conformational change in the nuclear receptors, triggering the transcription of specific genes including these encoding for various metabolic and cellular processes such as fatty acid oxidation [51] . Thus, we presumed that combination treatment-induced ROS production may be caused by fatty acid β-oxidation and oxidative phosphorylation.
To confirm this hypothesis, we determined that ROS production induced by combination treatment was impaired after CPT1 knockdown or oligomycin A addition (Fig. 6E, F) . These results further demonstrated that β-oxidation and oxidative phosphorylation were the main sources of ROS induced by ω-3 PUFAs and Rp. Next, to test whether combinationinduced metabolic shifts were associated with a change in mitochondrial ATP production, we analyzed ATP levels after the addition of 2-DG (an inhibitor of glycolysis), CB839 (an inhibitor of glutaminase), etomoxir (an inhibitor of fatty acid oxidation), and oligomycin A (an inhibitor of fatty acid oxidation). As shown in Fig. 6G , ATP levels in the combinationtreated cells were almost insensitive to 2-DG and CB839 treatment. In contrast, inhibition of oxidative phosphorylation and β-oxidation by oligomycin A and etomoxir showed that ATP levels were more dependent on mitochondria. These results further demonstrated that the combination treatment changed the energy consumption and production of cancer cells.
Combination treatment suppresses tumor growth in xenograft models
To evaluate the anticancer efficacy of the combination treatment on breast cancer in vivo, we used MDA-MB-231 cancer cell xenografts in athymic nu/nu mice as representatives of the in vivo model. Neither Rp nor EPA significantly inhibited tumor growth when administered alone compared with the control group (Fig. 7A) . However, the combination treatment caused a significant reduction in tumor growth in a time-dependent manner. At the end of the treatment period, the average tumor volumes in the combination treatment groups were significantly smaller than those in the other groups (Fig. 7A) . Moreover, the tumor mass showed the same trend (Fig. 7B) . A number of studies have confirmed that Ki67 protein expression is a strong indicator of patient outcome [52] ; therefore, we determined the Ki67 expression in each group. Tumor tissues were collected, and Ki67 expression was assessed using immunohistochemistry (IHC). A significant decrease in Ki67 expression was observed following treatment with Rp+EPA compared with EPA and Rp treatment alone (Fig. 7C,  D) . Clinical investigations have shown that metabolic abnormalities consistently occurred in patients during treatment with Rp [9, 53] . To determine whether EPA supplementation improved Rp-induced metabolic disorders, serum biochemical indexes were measured, including serum levels of TG, TC, HDL-C, and LDL-C. EPA completely reversed Rp-induced hypercholesterolemia and hypertriglyceridemia (Fig. 7E) . To determine whether the cell death mechanism observed in vitro could also be detected in the xenograft model, the key proteins in tumor tissues were analyzed. The in vivo data strongly supported the in vitro data; treatment with Rp+EPA significantly increased the key enzymes of β-oxidation and oxidative phosphorylation, whereas the enzymes of glycolysis and glutamine metabolism were significantly reduced in mice that received this combination treatment (Fig. 7F) . Furthermore, we detected the level of MDA (one of the main oxidation products) and found that the combination treatment dramatically increased MDA production (Fig. 7G ), in accordance with our in vitro results. These data support the proposed therapeutic mechanism of ω-3 PUFA-supplemented Rp treatment.
Combination treatment suppresses tumorigenesis in the MMTV-PyVT breast cancer mouse model
The xenograft model has been shown to be inaccurate for predicting the clinical outcomes of novel drugs, because the mice used in experiments are immune-deficient and the tumor is not in situ. To evaluate anti-tumor activity, we used the transgenic strain FVB/NTg(MMTV-PyVT)634Mul/J (also known as PyVT) in this study as a novel in vivo model of highly aggressive breast cancer [54] . We also investigated whether the ROS scavenger NAC impeded the anti-tumor effects of the combination treatment in vivo. After euthanization, 
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Effect the weight of tumors in the combination-treated mice was significantly lower than that in the other groups of PyVT mice (Fig. 8A) . Moreover, Ki67 expression was in accordance with tumor weight (Fig. 8B, C) , and Rp-induced hypertriglyceridemia and hypercholesterolemia were completely reversed by ω-3 PUFA supplementation (Fig. 8D) . We also observed that MDA levels dramatically increased in combination-treated mice (Fig. 8E) . Addition of the ROS scavenger NAC significantly reduced the anti-tumor efficacy of Rp+EPA (Fig. 8A-C) . These results further demonstrated the possible mechanism of the combination treatment.
Because Rp and ω-3 PUFAs are safe to use in clinical applications, we did not investigate the toxicity of the combination treatment in our experiment, but measured the change in body weight and conducted a liver biopsy in each group. We did not find any significant change in the body weight or in the liver biopsy (Fig. 8F, G) , suggesting that the combination treatment was a safe and effective anti-tumor strategy. 
Discussion
PI3K/Akt/mTOR pathway inhibitors used most commonly in clinical applications target a more distal pathway component, the mTOR. Rp, the prototypic mTOR inhibitor, was discovered in 1975 as a potent anti-fungicide, and its ability to inhibit the proliferation of cancer cell lines was shown more than 20 years ago [4, 5] . However, a major obstacle in the use of the Rp therapy in breast cancer is the occurrence of drug resistance and dyslipidemia [7, 9] . Clear evidence has linked metabolic disorders to a high risk of incidence as well as poor clinical outcomes of breast cancer. Furthermore, changes in the levels of adipokines caused by obesity are associated with the initiation and progression of breast cancer. Therefore, Rp 
Figure8
Cellular [29] . Therefore, disruption of autophagic flux may be the main reason underlying improved drug resistance.
Previous research has demonstrated that Rp combined with an ROS inducer EF24 significantly induces cancer cell death via ROS production [55] . Because ω-3 PUFAs are highly active molecules, we presumed that the synergistic effect of Rp combined with ω-3 PUFAs is related to ROS production, which can directly cause cytotoxicity or influence intracellular signaling pathways, resulting in growth inhibition or death of tumor cells. The results showed that the synergistic effects of the ω-3 PUFA+Rp combination on cell death were caused by ROS production, which may have been related to the degree of unsaturation.
Intracellular ROS is mainly generated through various metabolic pathways [56, 57] . Numerous published studies have demonstrated that mTOR senses the energy supply, nutrients, growth factors, and other conditions in the tumor microenvironment, and that TORC1 complex activity is necessary for appropriate glycolysis, glutamine consumption, the pentose-phosphate pathway, and lipid and nucleotide synthesis [48] . Moreover, ω-3 PUFAs not only as a source of fuel but also as bioactive components participate in cancer metabolism [49] . Therefore, we postulated that combination treatment-induced ROS production may be attributed to metabolic alterations. Multiple classical methods (e.g., western blotting, seahorse experiments, ATP production, metabonomics) have demonstrated that combination treatment-induced ROS was indeed a result of fatty acid oxidation. Furthermore, combination treatment significantly inhibited glycolysis and glutamine metabolism, which are required for the proliferation and survival of cancer cells. In addition, Rp and ω-3 PUFAs played different roles in metabolism regulation. The inhibition of glycolysis and glutamine metabolism was mainly dependent on Rp treatment, while the increase in β-oxidation and oxidative phosphorylation was mainly due to the addition of ω-3 PUFAs. After Rp treatment, the metabolism of glucose and glutamine was blocked, and cancer cells had no choice but to use the exogenous fatty acids (ω-3 PUFAs) for ATP production (Fig. 9) . However, the generous utilization of ω-3 PUFAs resulted in ROS production, which led to cell death. Therefore, it might be better for breast cancer patients to be pre-treated with Rp before being administered ω-3 PUFAs. 
